hotspot -WSS

hotspot

author：comprehensive 2025-09-29 21:12:56 - browse：55

LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the booming area of targeted radiation therapies for cancer.

AstraZeneca will pay $2 billion in cash upfront for Fusion, a price that at $21 a share is nearly double Fusion’s closing share price on Monday. If certain regulatory milestones are met, AstraZeneca will pay another $3 a share, or roughly $400 million.

Fusion specializes in developing radiopharmaceuticals, also known as radioconjugates or radioligands, which deliver radiation directly to tumors, guided by particular markers on cancer cells. The aim is not only to minimize the risk of damaging surrounding, healthy tissue, but also to reach tumors that traditional radiation can’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Sana to lay off nearly a third of staff, de

focus

leisure time

WSS

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

The explosion of genetic testing requires a new approach

Sana to lay off nearly a third of staff, de

Chan Zuckerberg Biohub Chicago to focus on inflammation

A virus, fished out of a lake, may have saved a man’s life

FDA rejects Alnylam's heart disease treatment over insufficient data

hotspot

hotspot

hotspot

Walensky prepares to leave CDC — and Congress — behind

Impact of Dobbs ruling felt at reproductive medicine meeting

Medical leaders decry Supreme Court decision on affirmative action

Why Charlie Gard's case is so disturbing to Americans

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Liquid biopsy for lung cancer is launched by Delfi

Sports medicine is finally prioritizing gender equality

First Opinion Podcast: Long Covid needs a new approach

Apple is now the first public company to be valued at $3 trillion

FDA panel signals lack of confidence in Amgen cancer drug data

focus

Senate committee scrutinizes Medicare Advantage brokers

Chemotherapy drug shortage eases slightly but still widespread

FDA gives detailed accounting of AI

When women are denied an abortion, their children fare worse than peers

The explosion of genetic testing requires a new approach

Eli Lilly expects to double planned employment in Boston center

focus

entertainment

leisure time

hotspot